The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
UnitedHealth to cover Guardant Health’s Shield blood test for early colorectal cancer screening for adults 45 and older
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 6, 8:45 PM EDT

UnitedHealth to cover Guardant Health’s Shield blood test for early colorectal cancer screening for adults 45 and older

The move makes UnitedHealth’s commercial plans the first major U.S. insurer to include Guardant Health’s Shield blood test, expanding coverage for a non-invasive option aimed at detecting colorectal cancer earlier.

By The Apex Times Newsroom2 min readAI-assisted Apex article

UnitedHealth Group is adding coverage for Guardant Health’s Shield blood test for early colorectal cancer screening, according to a market report published Tuesday by Yahoo Finance.

The report says the coverage starts for eligible adults aged 45 and older, positioning the policy change as a first for a major commercial insurer in the U.S. With colorectal cancer, screening is often recommended starting at age 45 in the U.S., and a blood-based test could broaden access for people who do not undergo stool-based or colonoscopy screening at the same rate.

Guardant Health’s Shield test is designed to look for indicates associated with colorectal cancer using a blood sample. Under UnitedHealth’s coverage expansion, eligible members can access the test through their plan, the report says, though it does not provide details on the specific plan types included, member cost-sharing, or the criteria used by clinicians to determine eligibility.

The report frames the coverage decision as a notable channel shift for Shield, moving it from clinical availability into routine insurance reimbursement for a large swath of the commercial market.

A second market write-up also highlighted the coverage change, echoing that Shield’s blood test is now covered for eligible UnitedHealth Group members. That item did not, however, add specific contract terms or operational details about when reimbursement applies or how claims are processed.

Sector context matters because colorectal cancer screening is a high-stakes, long-running priority for payers and providers, linking screening choices to downstream utilization such as diagnostic follow-up procedures. Broad insurer coverage can increase patient uptake, which can affect how quickly screening targets are met across populations.

Still, UnitedHealth and Guardant have not disclosed in the cited report what percentage of members are covered, whether the change applies uniformly across all UnitedHealth commercial products, or how the reimbursement decision interfaces with physician ordering protocols and laboratory billing rules. The reporting also does not specify whether coverage is limited to certain risk profiles, test frequency intervals, or geographic regions.

What to watch next is how quickly claims and test volumes respond after coverage begins, and whether other large insurers follow with similar reimbursement policies for blood-based colorectal screening. Investors and clinicians will also look for further guidance on ordering, eligibility, and follow-up pathways after a positive or inconclusive result.

Why It Matters

  • Coverage by a large commercial insurer can materially increase patient access to blood-based colorectal screening, particularly for people who avoid or delay other screening methods.
  • Insurer reimbursement can influence clinical ordering behavior, laboratory testing volumes, and overall screening participation rates.
  • The decision could increase competitive pressure on other payers to evaluate coverage for non-invasive screening technologies.
  • It may also affect downstream care planning, since screening results can trigger diagnostic follow-up procedures.

Sources

Key Facts

  • UnitedHealth Group will cover Guardant Health’s Shield blood test for early colorectal cancer screening.
  • The coverage applies to eligible adults aged 45 and older.
  • The market report describes UnitedHealth as the first major commercial insurer to cover the Shield test.
  • The reports do not provide specific details on which UnitedHealth plan types are included or what member cost-sharing will be.
  • Additional market coverage also cited UnitedHealth’s decision as the reason for Shield coverage expansion for eligible members.

Healthcare Related

UnitedHealth to cover Guardant Health’s Shield blood test for early colorectal cancer screening for adults 45 and older | The Apex Times